Dáil Éireann Debate, Tuesday - 27 September 2016
540. Deputy Billy Kelleher asked the Minister for Health to outline the position regarding the evaluation of pembrolizumab; when he will make a decision on the introduction of this drug; and if he will make a statement on the matter. [26454/16]
View answerPembrolizumab is currently available for reimbursement for the treatment of melanoma through the National Cancer Control Programme's Oncology Hospital Drugs Management System. Details of the protocol for eligibility and treatment are available at http://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/347.pdf.
The HSE has also received an application for reimbursement of pembrolizumab for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC). The National Centre for Pharmacoeconomics recently completed a rapid review of pembrolizumab for this indication, and has recommended a full health technology assessment of the drug.
